Last reviewed · How we verify
Zelapar
At a glance
| Generic name | Zelapar |
|---|---|
| Also known as | orally disintegrating selegiline |
| Sponsor | Baylor College of Medicine |
| Target | Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Major depressive disorder
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Rhinitis
- Headache
- Insomnia
- Stomatitis
- Dyspepsia
- Constipation
- Vomiting
- Diarrhea
- Dysphagia
- Flatulence
Serious adverse events
- Chest Pain
- Dyskinesia
- Dyspnea
- Rash
- Skin Disorders
- Hypertension
- Ecchymosis
- Hypokalemia
- Depression
- Pharyngitis
Key clinical trials
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (PHASE1)
- Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
- Selegiline to Zelapar Switch Study in Parkinson Disease Patients (PHASE4)
- Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers (PHASE1)
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (PHASE2)
- Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease (PHASE4)
- Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease (PHASE4)
- Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |